RT Journal Article
SR Electronic
T1 A Multiple Peptides Vaccine against nCOVID-19 Designed from the Nucleocapsid phosphoprotein (N) and Spike Glycoprotein (S) via the Immunoinformatics Approach
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.05.20.106351
DO 10.1101/2020.05.20.106351
A1 Sahar Obi Abd Albagi
A1 Mosab Yahya Al-Nour
A1 Mustafa Elhag
A1 Asaad Tageldein Idris Abdelihalim
A1 Esraa Musa Haroun
A1 Mohammed Elmujtba Adam Essa
A1 Mustafa Abubaker
A1 Mohammed A. Hassan
YR 2020
UL http://biorxiv.org/content/early/2020/05/20/2020.05.20.106351.abstract
AB Due to the current COVID-19 pandemic, the rapid discovery of a safe and effective vaccine is an essential issue, consequently, this study aims to predict potential COVID-19 peptide-based vaccine utilizing the Nucleocapsid phosphoprotein (N) and Spike Glycoprotein (S) via the Immunoinformatics approach. To achieve this goal, several Immune Epitope Database (IEDB) tools, molecular docking, and safety prediction servers were used. According to the results, The Spike peptide peptides SQCVNLTTRTQLPPAYTNSFTRGVY is predicted to have the highest binding affinity to the B-Cells. The Spike peptide FTISVTTEI has the highest binding affinity to the MHC I HLA-B1503 allele. The Nucleocapsid peptides KTFPPTEPK and RWYFYYLGTGPEAGL have the highest binding affinity to the MHC I HLA-A0202 allele and the three MHC II alleles HLA-DPA1*01:03/DPB1*02:01, HLA-DQA1*01:02/DQB1- *06:02, HLA-DRB1, respectively. Furthermore, those peptides were predicted as non-toxic and non-allergen. Therefore, the combination of those peptides is predicted to stimulate better immunological responses with respectable safety.Competing Interest StatementThe authors have declared no competing interest.